Thousands of lawsuits have been filed against GSK, claiming their antacid Zantac caused a greater risk of cancer in its users, stating the main ingredient Ranitidine may be a human carcinogen.

The Shocking Truth" How did Zantac, once the world's most popular drug for acid reflux and heartburn, turn into a toxic ...

GSK (GSK) stock was downgraded by Guggenheim Securities to neutral after the company's Q3 revenue decline. Read more here.

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

Two of GSK Plc’s blockbuster vaccines delivered lower than expected sales in the third quarter after the British drugmaker ...

Operating profit at GSK fell by 86 per cent due to a charge related to the settlement of Zantac settlements the company said ...

Operating profit fell by 86 per cent, and earnings per share slumped due to a settlement charge of £1.8bn related to the Zantac lawsuits. The lawsuits arose after recipients of GSK’s heartburn ...

The pharmaceutical giant reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance ...

GSK (GSK) used its third-quarter trading update to draw a definitive line under the damaging litigation around its now discontinued heartburn medicine Zantac, by agreeing a settlement earlier in ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.